Texas attorney general sues Tylenol makers over autism claims

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and Kenvue, alleging they concealed risks linking Tylenol (acetaminophen) to autism when used during pregnancy. While the companies and major medical organizations like the American College of Obstetricians and Gynecologists deny any credible scientific evidence for such a link, this state-level litigation, following a previously dismissed federal case, introduces significant legal and reputational risks for the pharmaceutical firms, potentially impacting product sales and increasing regulatory scrutiny on a key over-the-counter medication.

Analysis

Texas Attorney General Ken Paxton has sued Johnson & Johnson (JNJ) and Kenvue (KVUE), alleging they concealed risks linking Tylenol (acetaminophen) to autism in children when used during pregnancy. Paxton claims the companies "betrayed America" and seeks to halt marketing asserting Tylenol's safety, despite the FDA advising consideration of limiting Tylenol use while stating no causal link is established.

Kenvue denies these allegations, asserting "no credible data" links acetaminophen to autism, a stance supported by major medical organizations like the American College of Obstetricians and Gynecologists. ACOG emphasizes acetaminophen's critical role for pregnant women, citing decades of research finding no reputable study establishing a causal link to neurodevelopmental disorders.

This state-level litigation follows a previous federal lawsuit with similar claims that was dismissed due to inconclusive expert witness research. The lawsuit, filed by a Trump ally, introduces a political dimension, alleging companies "willfully ignored and attempted to silence the science."

The negative per-ticker sentiment for JNJ and KVUE (-0.2 each) reflects potential reputational damage and prolonged legal battles, irrespective of scientific consensus. This presents a significant legal and public relations challenge, particularly for Kenvue as the current manufacturer of Tylenol.

Key Decisions for Investors

• Investors should closely monitor the progression of the Texas lawsuit against JNJ and KVUE, including any new scientific findings or regulatory actions by the FDA, given the mixed signals and political undertones
• Evaluate the potential for reputational damage and shifts in consumer sentiment for both companies, particularly Kenvue, as the lawsuit's visibility could impact brand trust despite scientific denials
• Consider Kenvue's specific financial exposure as the current Tylenol manufacturer, assessing potential legal defense costs and any future restrictions on marketing or sales